Veracyte's Revised Guidance Has Set a Bar the Street Still Refuses to Accept

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Veracyte reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings data.

Historical price action around Veracyte earnings reveals extreme volatility, with an average absolute Day +1 move of 14.64%—nearly double the Day 0 average of 2.14%. This pattern is consistent with after-hours reporting: the real fireworks happen the session after results drop. The most dramatic recent move came after Q2 2026 earnings (July 30, 2026), when the stock initially surged +7.31% on Day 0 in anticipation, then plunged -22.52% on Day +1 despite beating estimates—suggesting guidance or commentary disappointed investors.

The volatility cuts both ways. After Q1 2026 results (May 5, 2026), the stock barely moved on Day 0 (-1.43%) but then rocketed +24.93% on Day +1. Similarly, Q3 2025 (November 4, 2025) saw a modest Day 0 decline of -0.91% followed by a massive +27.46% surge on Day +1. The Day +1 range averages 13.52%, indicating that even when the directional move is smaller, intraday swings remain substantial.

Investors should prepare for significant post-earnings volatility. While the stock has delivered positive Day +1 moves in five of the last eight quarters, the magnitude of swings—both up and down—suggests that even strong beats don't guarantee upside, and guidance commentary appears to be the primary driver of next-day performance.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.32% expected move for the November 20 expiration (17 days out, encompassing the November 4 earnings release). This is substantially below the stock's average historical Day +1 move of 14.64%, suggesting options traders may be underestimating potential volatility. Given that six of the last eight earnings reports produced Day +1 moves exceeding 8%, and three exceeded 20%, the current implied move appears conservative relative to VCYT's established pattern of extreme post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment on Veracyte has improved recently, with the consensus recommendation now at 4.62 (solidly in Buy territory) compared to 4.36 one month ago. The shift reflects one analyst upgrading from Strong Sell, eliminating the sole bearish rating from the coverage universe. The current breakdown shows 10 Strong Buys, 1 Moderate Buy, and 2 Holds—a decidedly bullish tilt with 85% of analysts rating the stock a buy.

The average price target of $58.75 implies +17% upside from the current price of $50.29, with estimates ranging from a low of $45.00 to a high of $70.00. The wide target range—spanning $25 or 56% from low to high—reflects differing views on the company's growth trajectory and valuation multiple. The high-end target of $70.00 suggests some analysts see potential for +39% upside if execution remains strong and profitability accelerates.

The recent sentiment improvement is notable given the challenging near-term EPS outlook, with Q3 2026 expected to show -26.3% year-over-year decline. This suggests analysts are looking past the current quarter's tough comparison and focusing on the longer-term growth story. The consensus for 2027 calls for +13.6% EPS growth to $1.50, indicating expectations that margin pressure will ease and the company will return to a more normalized growth trajectory. The overwhelmingly bullish stance—with no sell ratings remaining—reflects confidence in Veracyte's competitive position in the cancer diagnostics market and its ability to drive sustained revenue growth even as it navigates near-term profitability headwinds.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 56% Buy signal, unchanged from last week but improved from 40% Buy one month ago. This strengthening technical picture heading into earnings reflects positive momentum that has built over the past month, though the signal remains in "Soft" territory rather than showing overwhelming conviction.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is cautiously positive but not overwhelming
• Medium-term (Hold): Neutral reading suggests the intermediate trend is in consolidation mode
• Long-term (100% Buy): Strong buy signal reflects solid strength in the longer-term trend, providing a supportive backdrop

Trend Characteristics: The trend is characterized as Soft in strength with Average direction, suggesting momentum is present but not forceful, and the directional bias is neither strongly bullish nor bearish—a relatively balanced setup heading into the high-stakes earnings release.

From a moving average perspective, VCYT is trading above its 10-day ($49.04), 20-day ($46.46), 50-day ($44.73), 100-day ($48.51), and 200-day ($42.90) moving averages, but below its 5-day ($50.36)—indicating a recent minor pullback within an otherwise upward trend structure. The stock sits +17% above its 200-day moving average, confirming the longer-term bullish bias reflected in the technical signals.

The 52-week range of $29.46 to $60.91 shows VCYT currently trading in the upper third of its annual range, suggesting the stock has room to run toward the high if earnings and guidance impress. However, the recent failure to hold above the 5-day moving average and the "Soft" trend strength suggest some near-term hesitation. The overall technical setup is cautiously supportive for earnings: the longer-term trend remains intact and moving averages are well-aligned, but the lack of strong momentum and the stock's proximity to recent highs mean there's limited technical cushion if results or guidance disappoint. Given the historical pattern of 14.64% average post-earnings moves, traders should expect the technical picture to be completely redrawn by the session following the release.